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abine/tenofovir and efavirenz are the most frequently prescribed drugs after diag-
nosis of HIV. More research, however, is required to better understand adverse
events and side effects.
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OBJECTIVES: Healthy People 2020 (HP2020) emphasized the use of community ser-
vices for prevention and treatment of infectious diseases. Pharmacists are in a
unique position to helpwith this goal. This study comparednational immunization
rates to immunization rates of Hispanic patients receiving clinical pharmacist in-
terventions in a community health center (CHC). METHODS: El Paso CHC Latino
patients who were referred to a clinical pharmacist for diabetes and met immuni-
zation criteria between January 1, 2010 to December 31, 2010 were included. The
pharmacist documented whether or not the patient met criteria for Hepatitis A
(HepA), Hepatitis B (HepB), Tetanus-diphtheria-acellular pertussis (Tdap), Pneumo-
cocal, Zoster and Influenza vaccines. If criteria were met and patient consented,
the vaccine(s) were administered. Vaccination rates were calculated by dividing
the number of patients vaccinated by the number of eligible patients. Study immu-
nization rates (SIRs) were comparedwith the latest available (2009) national overall
(OIRs) and the Hispanic immunization (HIRs) rates. RESULTS: For included patients
(N336), HepA SIR was 32.7%, which was higher than both the OIR (9.8%) and HIR
(8.5%). The Zoster SIR (10.1%)was similar to the OIR (10.0%), but higher than theHIR
(4.8%). The Pneumococal SIRs (46.2%: 19-64 years; 65 years: 39.4%) were higher
than HIR in both age groups (12.1%, 40.4%, respectively). It was only higher, how-
ever, in the overall group aged 19-64 years (17.5%), but not in the 65 age group
(60.6%). The influenza SIR was 27.1%, which was higher than the HIR (22.0%), but
lower than the OIR (33.6%). The SIR for HepB (14.6%) and Tdap (42.0%) were lower
than both national rates (HIR:41.8%, 36.7%; and OIR:50.8%, 48.7%, respectively).
CONCLUSIONS: Pharmacist’s immunization rates among Latino patients were
higher when compared to Hispanic national rates for HepA, Zoster, and Pneumo-
cocal and influenza. Community pharmacists can play an instrumental role in
reducing infectious diseases health disparities.
INFECTION – Cost Studies
PIN8
THE ECONOMIC IMPACT OF ADDING CEFTAROLINE FOSAMIL TO HOSPITAL
FORMULARY FOR COMMUNITY ACQUIRED BACTERIAL PNEUMONIA: A
HOSPITAL BUDGET IMPACT ANALYSIS IN THE UNITED STATES
Huang XY1, Lodise T2, Friedland D3, Beresford EJ1
1Forest Research Institute, Inc, Jersey City, NJ, USA, 2Albany College of Pharmacy and Health
Sciences, Albany, NY, USA, 3Cerexa, Inc. (a wholly-owned subsidiary of Forest Laboratories, Inc,
New York, NY), Oakland, CA, USA
OBJECTIVES: Ceftaroline fosamil (CPT, TEFLARO
®
) is a new, broad-spectrum, bac-
tericidal cephalosporin approved in the US for the treatment of community-ac-
quired bacterial pneumonia (CABP). In two randomized controlled CABP trials
(NCT00621504, NCT00509106), clinical cure rates in the modified intent-to-treat
(MITT) efficacy population were 82.6% for CPT and 76.6% for ceftriaxone. Response
rates at Day 4 (MITT population, N141) were 69.6% and 58.3% for CPT and ceftri-
axone. The objective was to assess the budgetary impact of adding CPT to a US
hospital formulary. METHODS: A three-year hospital budget impact model was
constructed to evaluate patients hospitalized with CABP requiring intravenous (IV)
antimicrobial therapy and having PORT risk class scores of III or IV. Patients were
randomized to receive CPT 600mg IV q12h or 1g ceftriaxone IV q24h for 5–7 days.
Clinical cure rates were assumed to be similar to those from CPT phase 3 CABP
trials. Patients failing initial treatment were assumed to be treated successfully
with second-line antibiotic therapy. Length of stay and total cost per hospital day
(by success or failure with initial treatment) were estimated based on a large data-
base from over 100 US hospitals. Other model inputs included: annual number of
CABP admissions; projected annual case growth rate; proportion of CABP target
population initially treated with ceftriaxone; expected proportion of CABP target
population to be treated with CPT; drug cost; cost of antibiotic administration; cost
of second-line antibiotic therapy for patients failing initial therapy. A sensitivity
analysis using 95% confidence limits of clinical cure rates from phase 3 trials pro-
vided varying estimates. RESULTS: Estimated total cost for treating a CABP patient
with CPT is $1102 lower ($18,925 vs. $20,027) than treating a similar patient with
ceftriaxone (sensitivity analysis range: -$6 to -$2,223). CONCLUSIONS: Model esti-
mates indicate adding ceftaroline to formulary does not negatively impact a hos-
pital CABP budget.
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OBJECTIVES: Daptomycin is a cyclic lipopeptide antibiotic that has been commer-
cially available in Europe since 2006. Daptomycin has rapid bactericidal activity
against MRSA and is indicated for gram-positive infections including complicated
skin and skin structure infections (cSSSI), right-sided infective endocarditis and
Staphylococcus aureus bacteremia (BSI). This study aims to quantify the budgetary
impact of utilizing Daptomycin for suspected gram-positive cSSSI and BSI in
Germany.METHODS: A budget impact model was developed to compare the total
direct costs of utilizing vancomycin, linezolid, daptomycin, and “other antibiotics”
as a single category. A decision tree was constructed on the basis of clinical guide-
lines and validated by clinicians. Clinical data and laboratory utilization and cost
data were derived from a comprehensive review of over 40 publications. Antibiotic
utilization and net drug costs were derived using syndicated data from Arlington
Medical Resources (AMR). RESULTS: On average, the total direct costs (drug acqui-
sition, lab monitoring, and hospital) of treating a cSSSI patient with the following
agents were: vancomycin €2598 (4%, 12% and 84%), linezolid €2742 (37%, 5%, and
58%), daptomycin €3,171 (30%, 7%, and 63%), and other antibiotics €1835 (2%, 10%,
and 88%). For BSI patients, total direct costs were: vancomycin €2359 (5%, 13% and
82%), linezolid €3951 (37%, 5%, and 58%), daptomycin €2135 (37%, 7%, and 56%), and
other antibiotics €3087 (4%, 10%, and 86%). Extrapolating these costs to an average
German hospital with 300 BSI and 1000 cSSSI patients and increasing daptomycin
use in BSI from 1% to 6% and in cSSSI from 0.3% to 1.4% would save the hospital
€30,151 and €2,971 per year, respectively. CONCLUSIONS: Using daptomycin for
treating cSSSI is budget neutral and using it for bacteremia patients is associated
with favorable economic outcomes when compared with other antibiotics.
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OBJECTIVES: Ceftaroline fosamil (CPT, Teflaro
®
) is a new, broad-spectrum, bacte-
ricidal cephalosporin approved in the United States for the treatment of acute
bacterial skin and skin structure infections (ABSSSI). In two randomized controlled
ABSSSI trials (NCT00424190, NCT00423657), clinical cure rates in the modified in-
tent-to-treat (MITT) population were 85.9%with CPT and 85.5%with vancomycin
aztreonam. Clinical response rates at Day 3 (MITT population, N797) were 74.0%
and 66.2% for CPT and vancomycin  aztreonam combination, respectively. The
objective was to assess the budgetary impact of adding CPT to a hospital formulary
in the United States. METHODS: A three-year hospital budget impact model was
constructed with three initial treatment options; CPT, vancomycin  aztreonam,
and other vancomycin-containing regimens. The target population was hospital-
ized adult, ABSSSI patients. Clinical cure rateswith initial treatmentwere assumed
to be similar to those fromCPT clinical trials. Patients failing initial treatment were
assumed to be treated successfully with a second-line antibiotic therapy. Length of
stay and cost per hospital day (by success or failure with initial treatment) were
estimated based on a large database from over 100 US hospitals. Other model
inputs included: annual number of ABSSSI admissions; projected annual case
growth rate; proportion of ABSSSI target population receiving vancomycin-con-
taining regimen; expected proportion of ABSSSI target population to be treated
with CPT; drug acquisition cost; cost of antibiotic administration; cost of vancomy-
cin monitoring. A sensitivity analysis using 95% confidence limits of clinical cure
rates provided varying estimates. RESULTS: Estimated total cost for treating an
ABSSSI patient with CPT is $313 lower ($13,804 vs. $14,117) than vancomycin 
aztreonam (sensitivity analysis range; $235 to -$833) and $71 lower ($13,804 vs.
$13,875) than other vancomycin-containing regimens (sensitivity analysis range;
$478 to -$1430). CONCLUSIONS: Model estimates indicate adding ceftaroline to
formulary does not negatively impact a hospital ABSSSI budget.
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OBJECTIVES: Assess economic costs of adverse events (AEs) among patients with
human immunodeficiency virus (HIV) treated with non-nucleoside reverse trans-
criptase inhibitors (NNRTIs) including delavirdine, efavirenz, etravirine, and
nevirapine. METHODS: Retrospective cohort study using medical and pharmacy
claims fromUS commercial orMedicare supplemental insurance patients between
January 1, 2004 to September 30, 2009. Adult HIV-patients initiating NNRTI (no
NNRTI use during 6 months prior to first dispensation [index date]) were selected.
AEs included rash, nausea/vomiting, diarrhea, dizziness, headache, sleep-related
symptoms, hepatotoxicity, lipid disorders, depression, anxiety, and self-injury. AE
episode-related care during the year post-initiation was identified by claims asso-
ciated with AE management. AE cases were matched 1:4 to non-AE controls by
propensity of having anAE. “Associated costs” included plan payments and patient
copayments directly related to managing AEs. “Incremental costs” of experiencing
an AE were calculated as the difference in total costs between patients with AE
during the period of each AE episode and non-AE controls (matched period).
RESULTS: The study included 2548 NNRTI users (mean age 43 years; 84%male; 87%
efavirenz; 29% experienced an AE). During 1-year post-index period, annual total
healthcare cost per patient in this study populationwas $27,751 (efavirenz: $26,704;
other NNRTIs: $34,993). Annual mean AE associated costs were $609 per patient
(efavirenz: $555; other NNRTIs: $979). Mean AE associated cost of care (duration)
per AE episode ranged from $586 (88 days) for lipid disorders, $975 (33 days) for
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rash, to $2,728 (78 days) for sleep-related symptoms and $4,434 (41 days) for nau-
sea/vomiting. Mean incremental cost per AE episode ranged from $1,581 (rash),
$2,033 (lipid disorders) to $12,834 (nausea/vomiting) and $22,321 (sleep-related).
CONCLUSIONS: Treatment-associated AEs are now essential considerations with
increased HIV patient longevity. In addition to clinical implications, economic
costs should be considered in NNRTI-containing treatment regimen decisions and
for estimating cost-effectiveness of therapy.
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OBJECTIVES:Drugs used in the treatment of Human Immunodeficiency Virus (HIV)
which form part of Highly Active Anti-retroviral Therapy (HAART) are usually ex-
pensive and may have serious side effects. The objective of this study was to
compare the costs and adverse events of a new therapeutic agent, Rilpivirine, with
an established agent, Efavirenz, used in the treatment of HIV, both of which form
part of HAART among treatment naïve patients.METHODS: Decision tree analysis
was used to compare the direct medical costs of using Rilpivirine versus Efavirenz
in HAART from the societal perspective. Drug costs were obtained from an online
drug information source and Red Book 2008. Base case probabilities of having an
adverse event were obtained from a published clinical trial comparing Rilpivirine
versus Efavirenz (N690). Costs for treating adverse events were obtained from the
Medical Expenditure Panel Survey Database (2008). All costs were converted into
2011 US dollars. Sensitivity analyses were performed to determine the effects of
variations in assumptions regarding drug costs and costs for treating adverse
events on study results. All analyses were conducted using the 2011 TreeAge Pro
Software. RESULTS: The analyses showed that Rilpivirine is the treatment of
choice in the first year of therapy with a net cost of $27,282 per patient for Rilpi-
virine as compared to $28,619 per patient for Efavirenz. These results were robust
to changes in assumptions about costs of adverse events. If the cost of Rilpivirine
was higher than $11,610 or if the cost of Efavirenz was lower than $6,387, Efavirenz
would be the treatment of choice. CONCLUSIONS: From a societal standpoint,
Rilpivirine as part of HAART costs less as compared to Efavirenz. Future studies
should aim at comparing Rilpivirine with other established drugs used in the treat-
ment of HIV.
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RECURRENT INFECTION
Quimbo RA1, Palli SR1, Singer J1, Strauss M2
1HealthCore, Inc., Wilmington, DE, USA, 2MESTRA Consulting, Inc., White Plains, NY, USA
OBJECTIVES: To determine the incremental economic burden associated with
Clostridium-difficile associated diarrhea (CDAD) among patient sub-populations at
elevated risk for recurrent CDAD: immunocompromised (IC), prior CDAD, concur-
rent antibiotic use (cABx), renally impaired (RI), inflammatory bowel disease (IBD),
and age  65 years (elderly) patients. METHODS: CDAD cases hospitalized with a
diagnosis of CDAD (ICD-9-CM: 008.45) having 12 months of prior health plan
eligibility and 18 years of age between January 1, 2005 and October 31, 2010 were
identified from the HealthCore Integrated Research Database (HIRDSM). CDAD
cases within each sub-population were matched to hospitalized controls without
CDAD diagnosis based on: age10 years, gender, preceding/in-hospital comorbidi-
ties (cardiovascular, pulmonary, haematopoietic, and musculoskeletal) and use of
antibiotics. Incremental hospital length of stay (LOS) and hospital costs were cal-
culated betweenmatched cases and controls usingmultivariate generalized linear
models using a Gamma distribution. Covariates were determined frompost-match
univariate analysis of baseline characteristics for each sub-population. RESULTS:
Post-match case-to-control ratios ranged from 1:1 to 1:3 for each sub-population
(IC: n3,586 cases; prior CDAD: n933 cases; cABx: n4,429 cases; RI: n5,533
cases; IBD: n1,206 cases; elderly: n10,933 cases). Post-match comparisons of
baseline characteristics indicated no significant (P0.05) difference in targeted
match criteria. Compared to controls in all sub-populations, CDAD cases had sig-
nificantly greater (P0.0001) hospital LOS (mean incremental days [95% C.I.]; IC: 8.4
[7.9-9.0]; prior CDAD: 2.9 [2.4-3.6]; cABx: 7.8 [7.4-8.3]; RI: 17.3 [16.4-18.3]; IBD: 3.3
[2.9-3.7]; elderly: 7.8[7.5-8.1]) and hospital costs (mean incremental USD [95% C.I.];
IC: $31.8K [28.5-35.5]; prior CDAD: 28.0K [19.7-40.0]; cABx: 36.3K [33.3-39.6]; RI:
$115.6K [105.2-127.1]; IBD: $11.2K [9.3-13.4]; elderly: $43.2K [40.9-45.7]).
CONCLUSIONS: This study demonstrates the significant incremental economic
burden associated with CDAD both within the hospital setting and from a payer
perspective. CDAD patients in each sub-population incurred significantly greater
hospital LOS and corresponding hospital costs relative to matched controls.
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OBJECTIVES: Complicated skin and skin structure infection (cSSSI) is a common
and costly condition. Telavancin, a bactericidal lipoglycopeptide antibiotic, was
approved in September 2009 as a once-daily therapy for cSSSI. A retrospective
analysis was conducted using the Premier database to compare hospital resource
utilization and costs of cSSSI patients treated with telavancin or daptomycin.
METHODS: Adults with a hospital admission diagnosis of cSSSI receiving telavan-
cin or daptomycin during 2010 were selected. cSSSI was defined by 2011 IDSA
guidelines using ICD-9-CM codes. Logistic regression predicting treatment choice
and clinical opinion were used to identify thematched variables: age, gender, race,
primary diagnosis of cSSSI, prior MRSA infection, APR SOI score, hospital location
of drug initiation, and obesity. Eighty telavancin admissions were matched to 80
daptomycin admissions. Length of stay (LOS) in the hospital and ICU, and post-
drug LOS were analyzed. Costs were calculated using patient billing data. Unad-
justed regression models with gamma distribution and a log link were utilized.
RESULTS: The mean age was 54 years and 64% were male in both groups. Major
underlying conditions included MRSA infection (35 vs. 23%), sepsis (26 vs. 28%),
diabetes (23 vs. 35%), and/or obesity (16 vs. 16%) (telavancin vs. daptomycin, re-
spectively). Patients receiving telavancin had less LOS (11.9 vs. 14.8 days), post-drug
LOS (7.9 vs. 8.8 days), ICU-LOS (3.2 vs. 4.0 days), total hospital costs ($29,791 vs.
$39,054), and pharmacy costs ($4,918 vs. $8,366). Due to large variance in the data,
however, nonewere statistically significant. Total dosing of study drugswas higher
(4,450 mg vs. 3,061 mg) and daily cost was lower ($283 vs. $367) for telavancin
patients. CONCLUSIONS: For all categories, consistently lower resource utilization
and costs in the telavancin group compared to the daptomycin group were ob-
served, although differences were not statistically significant.
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OBJECTIVES: Staphylococcus aureus is a common cause of nosocomial infections in
acute care hospitals. This study aimed to estimate the clinical and economic im-
pact of S. aureus infections associated with surgical procedures in US hospitals.
METHODS: The analysis used the 2009 US National Inpatient Sample data, repre-
senting a 20% sample of 1050 hospitals from 44 states. The seven surgical sub-
groups examined included vascular, cardiothoracic, general, orthopedic, neurosur-
gical, plastic, and GYN/GU surgeries. S. aureus infection rates, length of stay, total
hospital charges and in-hospital mortality were estimated. Multivariate models
adjusted for sampling weights were used for analyses that control for age, gender,
race, payer source, comorbidities, procedure type, admission type and hospital
characteristics. RESULTS: In total, there were 6,894,989 hospitalizations that in-
volved at least 1 of the 7 surgical subgroups among patients age  18. Surgical S.
aureus infectionwas reported as a discharge diagnosis in 61,783 admissions, or 0.90
per 100 admissions (95% CI, 0.85-0.94). S. aureus infection rates varied largely by
surgical subgroups, ranging from 0.12% in GYN/GU to 5.42% in plastic procedures.
The adjusted excess length of stay associated with S. aureus infection was 9.5 days
compared to procedures with no S. aureus infection, ranging from 4.6 days in or-
thopedic procedures to 12.8 days in general procedures. The excess hospital charge
associated with S. aureus infection was also significant at the adjusted mean of
$67,939 compared to no infection. The inpatients with S. aureus infection had 2.1
(95% CI, 1.9-2.3) times the odds of dying in the hospital than patients without S.
aureus infection. CONCLUSIONS: The total number of inpatient S. aureus infections
and its clinical and economic impact on US hospitals were substantial. Prevention
of S. aureus infections would improve clinical outcomes and benefit hospitals and
society in terms of decreased use of scarce health care resources.
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OBJECTIVES: This study aimed to evaluate the costs and outcomes of hospital-
acquired blood stream infections.METHODS: This case control retrospective study
captured data on inpatients in the private hospital for a period of 2 years. The case
group had patients who had developed hospital acquired blood stream infections
and they were matched with controls on the basis of age, primary diagnosis, and
severity of illness. While all the costs were included, the outcome measures ad-
optedwere discharge status, length of stay andmortality of patients.RESULTS:The
results are based on 30matched patients in each arm.While hypertension was the
chief co-morbidity present in both the arms, upto 37% of the patients had none.
Staphylococci and Acinetobacter bauminii/hemolyticus were found to the most com-
mon pathogens, of the 15 identified responsible for causing hospital-acquired
blood stream infections. Polymixins were the most commonly used antimicrobial,
prescribed to 12 patients, followed by Teicoplanin and Linezolid. The 11/30 & 14/30
patients improved in the case and the control group, respectively. The total LOS
and the ICU LOS was significantly higher in the case group compared to controls.
The crudemortality rate for the casewas 53% against 23% for controls. Themedian
of the total cost of treatmentwas statistically significantly higher for the case group
when compared to the control (p0.001). Drug costs accounted for over 50% of the
total costs of treatment. CONCLUSIONS: These results confirm that hospital-ac-
quired blood stream infections pose an additional burden of the health resources &
significantly affect the mortality.
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